On Friday, Following U.S. Stocks were among the “Top Gainers”: Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS)

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), with shares inclined 4.23%, closed at $38.16.

Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS), surged 3.88%, and closed at $2.41.

Latest NEWS regarding these Stocks are depicted underneath:

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc. (TTPH), declared the pricing of an underwritten public offering of 4,300,000 shares of ordinary stock for a public offering price of $35.00 per share. The gross proceeds to Tetraphase from this offering are predictable to be about $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Tetraphase. Tetraphase has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 645,000 shares of ordinary stock. All of the shares of ordinary stock to be sold in the offering are to be sold by Tetraphase. The offering is predictable to close on or about March 17, 2015, subject to customary closing conditions.

BMO Capital Markets, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering and Nomura and SunTrust Robinson Humphrey are acting as co-managers for the offering.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical corporation, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc. (SNSS), stated financial results for the fourth quarter and year ended December 31, 2014. Loss from operations for the three months and year ended December 31, 2014 was $11.2 million and $45.0 million, respectively. As of December 31, 2014, cash, cash equivalents and marketable securities totaled $43.0 million.

Fourth Quarter 2014 and Recent Highlights:

Declared results from pivotal Phase 3 VALOR trial of vosaroxin and cytarabine in patients with first relapsed or refractory acute myeloid leukemia, and late breaking presentation at ASH Annual Meeting. In October 2014, Sunesis declared top-line results from the Phase 3 VALOR trial of vosaroxin and cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML) and, in December, the presentation of full results in a late-breaking oral presentation at the American Society of Hematology (ASH) Annual Meeting.

The randomized, double-blind, placebo-controlled Phase 3 VALOR trial enrolled 711 adult patients with first relapsed or refractory AML at 124 leading sites in 15 countries. Patients were stratified for age, geographic region and disease status and randomized one to one to receive either vosaroxin and cytarabine or placebo and cytarabine. Patients treated with vosaroxin achieved raised overall survival contrast to those treated with placebo (7.5 months vs 6.1 months, HR=0.87), the primary endpoint, but this difference did not achieve statistical significance (p=0.06). The complete remission (CR) rate, the sole secondary efficacy endpoint in the trial, did demonstrate a noteworthy difference for the vosaroxin combination arm (30.1% vs 16.3%, p < 0.0001).

In a pre-planned analysis accounting for the stratification factors at randomization, a noteworthy improvement in overall survival was demonstrated (HR=0.83, p=0.02). The pre-planned analysis of all treatment strata comprised of the following poor-prognosis patient categories: over 60 years old (7.1 months vs 5.0 months, HR=0.75, p=0.003, n=451), refractory disease (6.7 months vs 5.0 months, HR=0.87, p=0.23, n=301), and early relapsed disease (6.7 months vs 5.2 months, HR=0.77, p=0.04, n=256). Outcomes in patients under 60 years old or with late relapsed disease were comparable between treatment arms, with no improvement in overall survival. Across all strata, the CR and Composite CR (CR+CRp+CRi) rates were higher in the vosaroxin combination arm.

Given the complexity of interpreting the influence of transplantation therapy, a predefined analysis of overall survival censoring for hematopoietic stem cell transplantation was planned. In this analysis, patients receiving the vosaroxin combination had a median overall survival of 6.7 months as compared to 5.3 months for patients receiving placebo and cytarabine (HR=0.81, p=0.02).

Grade 3 or higher non-hematologic adverse events that were more ordinary in the vosaroxin combination arm were gastrointestinal and infection-related toxicities, compriseent with those observed in previous corporation trials. The rate of serious adverse events was 55.5% in the vosaroxin combination arm contrast to 35.7% in the placebo and cytarabine arm. All-cause mortality was comparable between the treatment arms (7.9% vs 6.6% for 30-day and 19.7% vs 19.4% for 60-day).

Sunesis Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly practiced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.